L.L. Siu

A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC

Nicole G. Chau, Sébastien J. Hotte, E.X. Chen et al. · Annals of Oncology · 2011 · 157 citations · Full text

Medicine, Oncology, Pharmacology +14

METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours

L.L. Siu, Drew Rasco, S. P. Vinay et al. · Annals of Oncology · 2019 · 133 citations · Full text

Medicine, Oncology, Pharmacology +5

The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.

L.L. Siu, Dipanwita Banerjee, Rohini Khurana et al. · PubMed · 1998 · 74 citations

Medicine, Cancer Biology, Oncology +17

Summary of the International Conference on Onco-Nephrology: an emerging field in medicine

Anna Capasso, Ariella Benigni, Umberto Capitanio et al. · Kidney International · 2019 · 56 citations · Full text

Medicine, Nephrology, Oncology +12

Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study.

Howard A. Burris, L.L. Siu, J. R. Infante et al. · Journal of Clinical Oncology · 2011 · 51 citations

Medicine, Oncology, Pharmacology +15